JP6441947B2 - キノリンを基にしたキナーゼ阻害剤 - Google Patents

キノリンを基にしたキナーゼ阻害剤 Download PDF

Info

Publication number
JP6441947B2
JP6441947B2 JP2016549431A JP2016549431A JP6441947B2 JP 6441947 B2 JP6441947 B2 JP 6441947B2 JP 2016549431 A JP2016549431 A JP 2016549431A JP 2016549431 A JP2016549431 A JP 2016549431A JP 6441947 B2 JP6441947 B2 JP 6441947B2
Authority
JP
Japan
Prior art keywords
pyridin
mmol
quinolin
methylbutyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016549431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017504652A5 (enExample
JP2017504652A (ja
Inventor
リチャード・エイ・ハーツ
ビジャイ・ティ・アフジャ
ジョン・イー・マコー
ジョアン・ジェイ・ブロンソン
ビレシュワル・ダスグプタ
キャロリン・ダイアン・ジアーバ
スシール・ジェタナンド・ナラ
マヘスワラン・シバサンバン・カラトルブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2017504652A publication Critical patent/JP2017504652A/ja
Publication of JP2017504652A5 publication Critical patent/JP2017504652A5/ja
Application granted granted Critical
Publication of JP6441947B2 publication Critical patent/JP6441947B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2016549431A 2014-01-31 2015-01-23 キノリンを基にしたキナーゼ阻害剤 Active JP6441947B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461934152P 2014-01-31 2014-01-31
US61/934,152 2014-01-31
PCT/US2015/012649 WO2015116492A1 (en) 2014-01-31 2015-01-23 Quinoline-based kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2017504652A JP2017504652A (ja) 2017-02-09
JP2017504652A5 JP2017504652A5 (enExample) 2017-10-19
JP6441947B2 true JP6441947B2 (ja) 2018-12-19

Family

ID=52474081

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016549431A Active JP6441947B2 (ja) 2014-01-31 2015-01-23 キノリンを基にしたキナーゼ阻害剤

Country Status (9)

Country Link
US (1) US9932320B2 (enExample)
EP (1) EP3099673B1 (enExample)
JP (1) JP6441947B2 (enExample)
CN (1) CN106132951B (enExample)
CA (1) CA2937501A1 (enExample)
EA (1) EA201691397A1 (enExample)
ES (1) ES2701903T3 (enExample)
MX (1) MX2016009352A (enExample)
WO (1) WO2015116492A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3019475A1 (en) 2013-07-08 2016-05-18 Bristol-Myers Squibb Company Aryl amide kinase inhibitors
ES2678877T3 (es) 2013-10-11 2018-08-20 Bristol-Myers Squibb Company Inhibidores de pirrolotriazina quinasa
KR102379518B1 (ko) 2014-04-02 2022-03-25 브리스톨-마이어스 스큅 컴퍼니 비아릴 키나제 억제제
WO2016164295A2 (en) * 2015-04-10 2016-10-13 Bristol-Myers Squibb Company Fused pyridines as kinase inhibitors
WO2017059085A1 (en) 2015-10-01 2017-04-06 Bristol-Myers Squibb Company Biaryl kinase inhibitors
US10246469B2 (en) 2015-10-01 2019-04-02 Bristol-Myers Squibb Company Biaryl kinase inhibitors
BR112018007128A2 (pt) * 2015-10-09 2018-11-06 Agency Science Tech & Res compostos para a inibição de câncer e epigênese
EP3260445A1 (en) 2016-06-24 2017-12-27 Universität Konstanz Compounds for use as an anti-bacterial or anti-fungal agent and as a zinc sensor
CN107501180B (zh) * 2017-09-13 2020-06-05 新乡医学院 一种喹啉-4-甲酰胺类化合物的合成方法
EP3502095A1 (en) 2017-12-22 2019-06-26 Universität Konstanz Compound for use against pathogenic neisseria and haemophilus species and moraxella catarrhalis
CN109734705B (zh) * 2019-02-01 2021-09-28 浙江工业大学 一种经脱卤烷基化制备n-杂环芳烃衍生物的方法
JP7534390B2 (ja) * 2019-09-12 2024-08-14 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１の阻害剤
CN113387965A (zh) * 2021-06-17 2021-09-14 南京邮电大学 一种有机电子受体材料及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5553801A (en) * 2000-04-24 2001-11-07 Bristol Myers Squibb Co Heterocycles that are inhibitors of impdh enzyme
KR102085121B1 (ko) * 2012-03-09 2020-03-05 렉시컨 파마슈티컬스 인코퍼레이티드 이미다조[1,2-b]피리다진계 화합물, 그를 포함하는 조성물 및 그의 용도
RU2014140735A (ru) * 2012-03-09 2016-04-27 Лексикон Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ ПИРАЗОЛО[1, 5-a]ПИРИМИДИНА, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HUE036040T2 (hu) * 2012-03-09 2018-06-28 Lexicon Pharmaceuticals Inc Adaptor-asszociált kináz 1 gátlása fájdalom kezelésére
US8703953B2 (en) * 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
US20170239249A1 (en) 2014-09-30 2017-08-24 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors

Also Published As

Publication number Publication date
US20160332985A1 (en) 2016-11-17
EP3099673A1 (en) 2016-12-07
CN106132951A (zh) 2016-11-16
EA201691397A1 (ru) 2016-11-30
CA2937501A1 (en) 2015-08-06
US9932320B2 (en) 2018-04-03
ES2701903T3 (es) 2019-02-26
EP3099673B1 (en) 2018-09-26
MX2016009352A (es) 2016-10-13
WO2015116492A1 (en) 2015-08-06
CN106132951B (zh) 2019-02-12
JP2017504652A (ja) 2017-02-09

Similar Documents

Publication Publication Date Title
JP6441947B2 (ja) キノリンを基にしたキナーゼ阻害剤
JP7033764B2 (ja) Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体
JP6563623B1 (ja) ピリドピリミジノンｃｄｋ２／４／６阻害剤
EP3331876B1 (en) Modulators of ror-gamma
TWI599562B (zh) 作爲ｔｔｘ－ｓ阻斷劑之醯胺衍生物
JP2022507231A (ja) がんの処置のためのＨＰＫ１阻害剤としての２，３－ジヒドロ－１Ｈ－ピロロ［３，４－ｃ］ピリジン－１－オン誘導体
US9708337B2 (en) Aryl amide-based kinase inhibitors
AU2018257203B2 (en) Novel tetrahydronaphthyl urea derivatives
TWI664166B (zh) Ｋｃｎｑ２至５通道活化劑
US10035777B2 (en) Heterocyclic kinase inhibitors
JP6243539B2 (ja) アリールエーテルをベースとするキナーゼ阻害剤
US20150284381A1 (en) Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors
WO2019205983A1 (zh) 氧杂螺环类化合物及其制备方法和用途
JP2015510881A (ja) アリールエーテルベースのキナーゼ阻害剤
JP2018199712A (ja) アリールアミドキナーゼ阻害剤
EP3200797A1 (en) Quinazoline-based kinase inhibitors
CA2831356A1 (en) Imidazo [1,2-a]pyridine_compounds for use in therapy
CN111377873B (zh) 氨基嘧啶化合物及其制备方法和用途
JP2020528922A (ja) アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体
TW202340198A (zh) 靶向ｍａｌｔ１的蛋白降解化合物、包含其的醫藥組合物及其用途
TWI591064B (zh) ２－吡啶酮化合物
WO2017198180A1 (zh) 一类含氟三氮唑并吡啶类化合物及其制备方法、药物组合物和用途
JP6048533B2 (ja) ２−ピリドン化合物を含有する医薬
AU2023225437A1 (en) Indazole compound and pharmaceutical use thereof
TW202434599A (zh) 造血前驅細胞激酶1之吡啶酮及嘧啶酮抑制劑

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170907

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181102

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181122

R150 Certificate of patent or registration of utility model

Ref document number: 6441947

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250